Biotechnology
Technology
Health

Bio-Techne

$197.83
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$1.08 (0.55%) Today
+$1.08 (0.55%) Today

Why Robinhood?

You can buy or sell Bio-Techne and other stocks, options, ETFs, and crypto commission-free!

About

Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Biotechnology, Protein Platforms, Diagnostics, and Corporate. Read More The Biotechnology segment supplies specialized proteins, such as cytokines and growth factors, immunoassays, antibodies and related reagents, as well as in situ hybridization, media and other cell culture products and reagents to the biotechnology research community. The Protein Platforms segment develops, manufactures, and sells tools to simplify protein analysis. The Diagnostics segment includes blood chemistry and blood gas quality controls, hematology instrument controls, diagnostic immunoassays, and other bulk and custom reagents for the in vitro diagnostic market worldwide. The company was founded on 1976 and is headquartered in Minneapolis, MN.

Employees
1,943
Headquarters
Minneapolis, Minnesota
Founded
1976
Market Cap
7.42B
Price-Earnings Ratio
79.43
Dividend Yield
0.87
Average Volume
212.75K
High Today
$198.07
Low Today
$195.13
Open Price
$197.23
Volume
3.16K
52 Week High
$206.04
52 Week Low
$132.75

Collections

Biotechnology
Technology
Health
Medical
Media
Gas
Oil and Gas
Fossil Fuel

News

Simply Wall St24h

Is Bio-Techne Corporation’s (NASDAQ:TECH) CEO Paid Enough Relative To Peers?

Chuck Kummeth became the CEO of Bio-Techne Corporation (NASDAQ:TECH) in 2013. First, this article will compare CEO compensation with compensation at similar sized companies.

1
TradingNewsNowMar 13

Latest Performance: Bio-Techne Corp (NASDAQ: TECH)

Bio-Techne Corp is in the healthcare sector and is part of the biotechnology industry. The company CEO is Charles R. Kummeth. Bio-Techne Corp and is a biotechnology company which develops, manufactures and sells biotechnology reagents, instruments and clinical diagnostic products. Previous Intraday Trading Performance: The TECH stock showed a previous change of 0.72% with an open at 192.11 and a close of 193.36. It reached an intraday high of 194.37 and a low of 191.00. PR Newswire: Bio-Techne Scores A T...

10
Yahoo FinanceMar 5

Bio-Techne Scores A Trio Of CiteAb 2019 Awards

MINNEAPOLIS, March 5, 2019 /PRNewswire/ -- Bio-Techne, a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, was honored with three prestigious 2019 CiteAb Awards.

3

Earnings

$0.88
$1.03
$1.19
$1.34
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Estimated
—
Actual
Expected May 1, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.